The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Efficacy and safety of rituximab in moderately‐to‐severely active systemic lupus erythematosus: The randomized, double‐blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial
Open accessAbstract
Objective: B cells are likely to contribute to the pathogenesis of systemic lupus erythematosus (SLE), and rituximab induces depletion of B cells. The Exploratory Phase II/III SLE Evaluation of Rituximab (EXPLORER) trial tested the efficacy and safety of rituximab versus placebo in patients with moderately‐to‐severely active extrarenal SLE. Methods: Patients entered with ≥1 British Isles Lupus Assessment Group (BILAG) A score or ≥2 BILAG B scores despite background immunosuppressant therapy, which was continued during the trial. Prednisone was added and subsequently tapered. Patients were randomized at a ratio of 2:1 to receive rituximab (1,000 mg) or placebo on days 1, 15, 168, and 182. Results: In the intent‐to‐treat analysis of 257 patients, background treatment was evenly distributed among azathioprine, mycophenolate mofetil, and methotrexate. Fifty‐three percent of the patients had ≥1 BILAG A score at entry, and 57% of the patients were categorized as being steroid dependent. No differences were observed between placebo and rituximab in the primary and secondary efficacy end points, including the BILAG‐defined response, in terms of both area under the curve and landmark analyses. A beneficial effect of rituximab on the primary end point was observed in the African American and Hispanic subgroups. Safety and tolerability were similar in patients receiving placebo and those receiving rituximab. Conclusion: The EXPLORER trial enrolled patients with moderately‐to‐severely active SLE and used aggressive background treatment and sensitive cutoffs for nonresponse. No differences were noted between placebo and rituximab in the primary and secondary end points. Further evaluation of patient subsets, biomarkers, and exploratory outcome models may improve the design of future SLE clinical trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1992) · PubMed · Cited by 33,716
The MOS 36-ltem Short-Form Health Survey (SF-36): I. Conceptual Framework and Item Selection
Ware, J. E., & Sherbourne, C. D. (1992) · Medical Care · doi:10.1097/00005650-199206000-00002 · Cited by 30,033
(2016) · Diagnostic Imaging: Brain · doi:10.1016/b978-0-323-37754-6.50094-4 · Cited by 3,990
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis
Edwards, J. C. W., Szczepański, L., Szechiński, J., Filipowicz-Sosnowska, A., Emery, P., Close, D. R., Stevens, R. M., & Shaw, T. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032534 · Cited by 2,623
Development of Autoantibodies before the Clinical Onset of Systemic Lupus Erythematosus
Arbuckle, M. R., McClain, M. T., Rubertone, M. V., Scofield, R. H., Dennis, G. J., James, J. A., & Harley, J. B. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021933 · Cited by 2,578
Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20
Reff, M., Carner, K., Chambers, K., Chinn, P., Leonard, J., Raab, R., Newman, R., Hanna, N., & Anderson, D. (1994) · Blood · doi:10.1182/blood.v83.2.435.435 · Cited by 1,999
Cohen, S. B., Emery, P., Greenwald, M. W., Dougados, M., Furie, R. A., Genovese, M. C., Keystone, E. C., Loveless, J. E., Burmester, G., Cravets, M. W., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22025 · Cited by 1,638
Rahman, A., & Isenberg, D. A. (2008) · New England Journal of Medicine · doi:10.1056/nejmra071297 · Cited by 1,632
Self-citationRusso, J., Trujillo, C. A., Wingerson, D., Decker, K., Ries, R., Wetzler, H., & Roy-Byrne, P. (1998) · Medical Care · doi:10.1097/00005650-199805000-00015 · Cited by 1,308
Renal-Limited “Lupus-Like” Nephritis: How Much of a Lupus
Maziad, A. S. A., Torrealba, J., Seikaly, M. G., Hassler, J. R., & Hendricks, A. R. (2017) · Case Reports in Nephrology and Dialysis · doi:10.1159/000475493 · Cited by 1,299
Emery, P., Fleischmann, R., Filipowicz‐Sosnowska, A., Schechtman, J., Szczepanski, L., Kavanaugh, A., Racewicz, A. J., van Vollenhoven, R. F., Li, N. F., Agarwal, S., et al. (2006) · Arthritis & Rheumatism · doi:10.1002/art.21778 · Cited by 1,060
Rahman, M. U. (2008) · Essentials of Physical Medicine and Rehabilitation · doi:10.1016/b978-1-4160-4007-1.50153-x · Cited by 1,019
Pathogenesis of systemic lupus erythematosus
Mok, C. C., & Lau, C. S. (2003) · Journal of Clinical Pathology · doi:10.1136/jcp.56.7.481 · Cited by 942
Maloney, D., Liles, T., Czerwinski, D., Waldichuk, C., Rosenberg, J., Grillo-Lopez, A., & Levy, R. (1994) · Blood · doi:10.1182/blood.v84.8.2457.2457 · Cited by 762
Anderson, K., Bates, M., Slaughenhoupt, B., Pinkus, G., Schlossman, S., & Nadler, L. (1984) · Blood · doi:10.1182/blood.v63.6.1424.1424 · Cited by 704
Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity
Lipsky, P. E. (2001) · Nature Immunology · doi:10.1038/ni0901-764 · Cited by 695
Manson, J. J., & Rahman, A. (2006) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-1-6 · Cited by 605
An open study of B lymphocyte depletion in systemic lupus erythematosus
Leandro, M. J., Edwards, J. C., Cambridge, G., Ehrenstein, M. R., & Isenberg, D. A. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10541 · Cited by 576
Self-citation(1993) · QJM: An International Journal of Medicine · doi:10.1093/oxfordjournals.qjmed.a068841 · Cited by 567
Gordon, C., Li, C. K., & Isenberg, D. A. (2010) · Medicine · doi:10.1016/j.mpmed.2009.10.006 · Cited by 565
Self-citationImportance of Cellular Microenvironment and Circulatory Dynamics in B Cell Immunotherapy
Gong, Q., Ou, Q., Ye, S., Lee, W. P., Cornelius, J., Diehl, L., Lin, W. Y., Hu, Z., Lu, Y., Chen, Y., et al. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.817 · Cited by 543
A Controlled Trial of Plasmapheresis Therapy in Severe Lupus Nephritis
Lewis, E. J., Hunsicker, L. G., Lan, S.-P., Rohde, R. D., & Lachin, J. M. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205213262101 · Cited by 473
Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus
Anolik, J. H., Barnard, J., Cappione, A., Pugh‐Bernard, A. E., Felgar, R. E., Looney, R. J., & Sanz, I. (2004) · Arthritis & Rheumatism · doi:10.1002/art.20592 · Cited by 456
Smith, K. G. C., Jones, R. B., Burns, S. M., & Jayne, D. R. W. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22046 · Cited by 400
Leandro, M. J., Cambridge, G., Edwards, J. C., Ehrenstein, M. R., & Isenberg, D. A. (2005) · Rheumatology · doi:10.1093/rheumatology/kei080 · Cited by 364
Self-citationThe role of B cells in lpr/lpr-induced autoimmunity.
Shlomchik, M. J., Madaio, M. P., Ni, D., Trounstein, M., & Huszar, D. (1994) · The Journal of experimental medicine · doi:10.1084/jem.180.4.1295 · Cited by 361
Tokunaga, M., Saito, K., Kawabata, D., Imura, Y., Fujii, T., Nakayamada, S., Tsujimura, S., Nawata, M., Iwata, S., Azuma, T., et al. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.057885 · Cited by 343
Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans
Dooley, M. A., Hogan, S., Jennette, C., Falk, R., & for the Glomerular Disease Collaborative Network (1997) · Kidney International · doi:10.1038/ki.1997.162 · Cited by 341
Depletion of B Cells in Murine Lupus: Efficacy and Resistance
Ahuja, A., Shupe, J., Dunn, R., Kashgarian, M., Kehry, M. R., & Shlomchik, M. J. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.179.5.3351 · Cited by 239
Cambridge, G., Leandro, M. J., Teodorescu, M., Manson, J., Rahman, A., Isenberg, D. A., & Edwards, J. C. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22211 · Cited by 230
Self-citationSurviving the butterfly and the wolf: mortality trends in systemic lupus erythematosus
Borchers, A. T., Keen, C. L., Shoenfeld, Y., & Gershwin, M. E. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2004.04.002 · Cited by 206
Neutropenia in Patients Treated with Rituximab
(2003) · New England Journal of Medicine · doi:10.1056/nejm200306263482620 · Cited by 189
Definition and treatment of lupus flares measured by the BILAG index
Gordon, C. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg382 · Cited by 141
Self-citation(2004) · Arthritis & Rheumatism · doi:10.1002/art.20628 · Cited by 138
Systemic lupus erythematosus in three ethnic groups. XX. Damage as a predictor of further damage
Alarcón, G. S. (2003) · British journal of rheumatology · doi:10.1093/rheumatology/keg481 · Cited by 128
A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus
Tanaka, Y., Yamamoto, K., Takeuchi, T., Nishimoto, N., Miyasaka, N., Sumida, T., Shima, Y., Takada, K., Matsumoto, I., Saito, K., et al. (2007) · Modern Rheumatology · doi:10.1007/s10165-007-0565-z · Cited by 126
From BILAG to BLIPS—disease activity assessment in lupus past, present and future
Isenberg, D. A., & Gordon, C. (2000) · Lupus · doi:10.1191/096120300672904669 · Cited by 109
Self-citationSmoking is a strong risk factor for rheumatoid nodules in early rheumatoid arthritis
Nyhäll-Wåhlin, B.-M., Jacobsson, L. T. H., Petersson, I. F., & Turesson, C. (2005) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2005.039172 · Cited by 101
van Vollenhoven, R., Gunnarsson, I., Henriksson, E. W., Sundelin, B., Österborg, A., Sh, J., & Klareskog, L. (2004) · Scandinavian Journal of Rheumatology · doi:10.1080/03009740410010227 · Cited by 93
Uribe, A. G., McGwin, G., Reveille, J. D., & Alarcón, G. S. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2003.11.005 · Cited by 87
Dysfunctional B cells in systemic lupus erythematosus
Renaudineau, Y., Pers, J., Bendaoud, B., Jamin, C., & Youinou, P. (2004) · Autoimmunity Reviews · doi:10.1016/j.autrev.2004.07.035 · Cited by 73
Effects of rituximab on resistant SLE disease including lung involvement
Reynolds, J. A., Toescu, V., Yee, C., Prabu, A., Situnayake, D., & Gordon, C. (2008) · Lupus · doi:10.1177/0961203308094653 · Cited by 66
Self-citationSutter, J. A., Kwan‐Morley, J., Dunham, J., Du, Y., Kamoun, M., Albert, D., Eisenberg, R. A., & Prak, E. T. L. (2008) · Clinical Immunology · doi:10.1016/j.clim.2007.11.012 · Cited by 62
Lu, T., Jonsdottir, T., van Vollenhoven, R., & Isenberg, D. A. (2008) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.091124 · Cited by 30
Self-citationSmeenk, R. J. T., Swaak, T. J. G., & Smeenk, R. J. T. (1987) · Clinical Rheumatology · doi:10.1007/bf02200721 · Cited by 27
Ehrenstein, M. R., Conroy, S. E., HEATH, J., et al. (1995) · Lara D. Veeken · doi:10.1093/rheumatology/34.3.257 · Cited by 27
Cited by
Tsokos, G. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1100359 · Cited by 2,736
2019 update of the EULAR recommendations for the management of systemic lupus erythematosus
Fanouriakis, A., Kostopoulou, M., Alunno, A., Aringer, M., Bajema, I., Boletis, J. N., Cervera, R., Doria, A., Gordon, C., Govoni, M., et al. (2019) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215089 · Cited by 2,011
Self-citationHahn, B. H., McMahon, M. A., Wilkinson, A., Wallace, W. D., Daikh, D. I., FitzGerald, J. D., Karpouzas, G. A., Merrill, J. T., Wallace, D. J., Yazdany, J., et al. (2012) · Arthritis Care & Research · doi:10.1002/acr.21664 · Cited by 1,463
Self-citationRovin, B. H., Furie, R., Latinis, K., Looney, R. J., Fervenza, F. C., Sanchez‐Guerrero, J., Maciuca, R., Zhang, D., Garg, J. P., Brunetta, P., et al. (2012) · Arthritis & Rheumatism · doi:10.1002/art.34359 · Cited by 1,461
Self-citationKaul, A., Gordon, C., Crow, M. K., Touma, Z., Urowitz, M. B., van Vollenhoven, R., Ruiz-Irastorza, G., & Hughes, G. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.39 · Cited by 1,391
Self-citation
Metadata
- Authors
- Merrill, J. T., Neuwelt, C. M., Wallace, D. J., Shanahan, J. C., Latinis, K. M., Oates, J. C., Utset, T. O., Gordon, C., Isenberg, D. A., Hsieh, H., Zhang, D., & Brunetta, P. G.
- Venue
- Arthritis & Rheumatism
- Publisher
- Wiley
- Published
- 2009-12-28
- Volume
- 62
- Issue
- 1
- Pages
- 222-233
- ISSN
- 0004-3591 (ISSN-L)
- 1529-0131
- OpenAlex
- W2046330020
- Cited by
- 1,409
- References
- 46
- FWCI
- 50.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.